A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 19 Jan 2012 Planned end date changed from 1 May 2009 to 1 Jan 2009 as reported by ClinicalTrials.gov.
- 19 Jan 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.